March 22nd 2024 Metal Neurotoxicity: Implications for the patients Martínez-Hernández et al. reviewed the role of microglia in metal neurotoxicity and their role in the development of neurodegenerative diseases. Read more
March 14th 2024 THA in the under twenties: Ceramic-on-Ceramic as the treatment of choice Clinical outcomes of total hip arthroplasty (THA) in teenage patients are still controversially discussed and there are still concerns related to the survival of implanted prostheses. Read more
February 27th 2024 Ceramic hip bearings continuously gaining ground in US healthcare Bearing material composition has proven to be crucial in determining the longevity and functionality of hip implants. Read more
February 6th 2024 Continued trend in ceramic use in Germany Ceramic Insights of EPRD - ENDOPROTHESENREGISTER DEUTSCHLAND (German Arthroplasty Registry) 2023. Read more
January 23rd 2024 Cobalt toxicity after hip arthroplasty Cobalt chromium alloy has been recognized by NIS as a toxic substance, and evidence has demonstrated that high blood levels of cobalt ions can lead to systemic effects in hip patients. Read more
October 18th 2023 Does vitamin D deficiency / insufficiency lead to worse outcomes in Total Joint Arthroplasty? According to recent data, there is a prevalence of vitamin D deficiency in the general US population of 41.6%. Read more
September 21st 2023 Italian Regional Registry Study – Modular head-neck adapter system & ceramic heads in revision hip arthroplasty The study published by Rizzoli’s group investigated the survival rates and reasons for re-revisions, with a focus on implant-related failures. Read more
September 5th 2023 Is there a difference in gait function of women treated with a ceramic resurfacing compared to women who received a conventional THA? According, to a recent study published by Prof. Justin Cobb and his group, the answer is YES! Read more
August 23rd 2023 PEEK-on-ZTA ceramic Total Disc Replacement PEEK-on-ZTA ceramic Total Disc Replacement has an acceptable safety profile with a success rate significantly greater than in the fusion control group: 93% vs 73.6% (P< .01). Read more